Flagship Pioneering has started Mirai Bio, a end-to-end biotech firm specialising in the creation of optimised genetic medicines.
The novel company's machine intelligence-based open platform aims to discover ways to deliver therapeutics to a wide range of tissue and cell types.
It also focuses on finding ways to successfully manufacture a medication, while also accelerating the commercialisation of gene therapies.
Mirai Bio will further advance the platform with an initial commitment of USD $50m from Flagship Pioneering.
According to the new company, its platform is fully enabled by high-throughput automation and in vivo multiplexing — allowing it to generate vast amounts of data that can be used for process optimisation.
The platform works to co-optimise the delivery, design and manufacture of gene therapies, boosting the chance of a CGT's success and eventual market introduction.
Hari Pujar, Founding President of Mirai and Operating Partner at Flagship Pioneering, said: “We are in the age of information molecules, yet enormous technological challenges in the delivery, cargo design, and manufacturing of these molecules have hindered the speedy and full realization of their potential,”
“We created Mirai to solve these key limitations through AI trained on high quantities of quality in vivo data. By applying machine intelligence to the design of every atom within the medicine and opening this platform to the entire industry, we will have vast collective data points rolling through our optimization loops, allowing a greater innovation advantage to benefit each partner on the Mirai platform.”
The Executive Chair at Mirai and Growth Partner, Flagship Pioneering, Travis Wilson, added: “Every new company with a payload idea faces the same challenge of either internally building high-quality, cost intensive delivery, design and manufacturing capabilities, or externally sourcing these components, which can be fragmented and suboptimal."
"Leveraging learnings from semiconductors as a centralized resource model that fueled the rapid advancement of tech, we’ve developed a solution that’s been hiding in plain sight: an open platform to unlock genetic medicine development. Through aggressive investment in our own capabilities and expertise, and by creating long-term partnerships with biotech and pharma leaders in the space, Mirai’s hope is to become the partner of choice and help bring more medicines into the world than we would ever achieve alone.”
